L M Rassokhina Selected Research

Reamberin

1/2017	[Anxiolytic and antidepressant effects of emoxipine, reamberin and mexidol in experimental diabetes mellitus].
1/2016	[The effect of reamberin and alpha-lipoic acid on the tolerance to acute cerebral ischemia in experimental diabetes mellitus].
3/2015	[Anxiolytic and antidepressant effects of 3-oxypiridine and succinic acid derivatives in alloxan diabetes].
1/2014	[Protective effect of 3-oxypyridine and succinic acid derivatives under conditions of acute alloxan-induced intoxication in mice].
1/2014	[Insulin potentiating and antidepressant effects of 3-oxypyridine and succinic acid derivatives].
1/2014	[The effect of 3-oxypyridine and succinic acid derivatives on the resistance to acute cerebral ischemia].
1/2014	[Anxiolytic and antidepressant effects of 3-oxypiridine and succinic acid derivatives in the acute phase of alloxan-induced diabetes in rats].
5/2013	Cerebroprotective effects of emoxipin, reamberin, and mexidol in alloxan diabetes.
1/2013	[Cerebroprotective effect of 3-oxypyridine and succinic acid derivatives in experimental diabetes mellitus].
1/2011	Effect of pro- and antioxidants on insulin sensitivity and glucose tolerance.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

L M Rassokhina Research Topics

Disease

12	Hyperglycemia 01/2017 - 03/2009
11	Experimental Diabetes Mellitus 01/2017 - 03/2009
5	Diabetes Mellitus 05/2012 - 01/2008
4	Diabetic Neuropathies (Diabetic Neuropathy) 03/2015 - 01/2008
3	Hyperlipidemias (Hyperlipidemia) 01/2011 - 01/2008
2	Brain Ischemia (Cerebral Ischemia) 01/2016 - 01/2014
2	Hypoxia (Hypoxemia) 01/2016 - 01/2011
2	Depressive Disorder (Melancholia) 03/2015 - 01/2014
2	Mood Disorders (Mood Disorder) 03/2015 - 01/2014
1	Anhedonia 11/2016
1	Stroke (Strokes) 01/2016
1	Anxiety Disorders (Anxiety Disorder) 04/2015
1	Ischemia 01/2014
1	Insulin Coma 01/2014
1	Hypercholesterolemia 05/2013
1	Hypertriglyceridemia 05/2013
1	hypoglycemic encephalopathy 04/2013
1	Learning Disabilities (Learning Disability) 01/2011
1	Insulin Resistance 01/2011
1	Cognitive Dysfunction 01/2011
1	Hypesthesia (Numbness) 01/2008
1	Paresthesia (Dysesthesia) 01/2008
1	Diabetic Foot 01/2008
1	Spasm (Spasms) 01/2008
1	Polyneuropathies (Polyneuropathy) 01/2008

Drug/Important Bio-Agent (IBA)

14	emoxypine succinateIBA 01/2017 - 01/2008
12	ReamberinIBA 01/2017 - 08/2009
12	6-methyl-2-ethyl-3-hydroxypyridineIBA 01/2017 - 03/2009
12	Thioctic Acid (Lipoic Acid)IBA 01/2016 - 01/2008
8	Succinic Acid (Succinate)IBA 01/2017 - 01/2011
6	3-oxypyridineIBA 01/2017 - 01/2011
6	AlloxanIBA 01/2014 - 01/2011
5	Antidepressive Agents (Antidepressants)IBA 01/2017 - 03/2009
4	Insulin (Novolin)FDA Link 01/2016 - 01/2011
3	Anti-Anxiety Agents (Anxiolytics)IBA 01/2017 - 01/2014
3	Glucose (Dextrose)FDA LinkGeneric 01/2016 - 08/2009
3	3-hydroxypyridineIBA 04/2015 - 01/2011
3	AntioxidantsIBA 05/2013 - 01/2011
1	Dexamethasone (Maxidex)FDA LinkGeneric 11/2016
1	FructosamineIBA 05/2013
1	CarbohydratesIBA 05/2013
1	Lipid PeroxidesIBA 05/2013
1	LipidsIBA 05/2012
1	alpha-Tocopherol FDA Link 05/2012
1	CholesterolIBA 05/2012
1	HeptanesIBA 05/2012
1	Nootropic Agents (Nootropics)IBA 01/2011
1	Neuroprotective AgentsIBA 01/2011
1	Indicators and Reagents (Reagents)IBA 01/2008

Therapy/Procedure

2	Therapeutics 01/2016 - 05/2013